HSRProj will be retired on September 14, 2021, no updates will be made to HSRProj after this date.
Detailed information about this transition can be found on the
June 3, 2021 Technical Bulletin post.
If you have questions or suggestions, please contact
NLM Customer Service.
Information about ongoing health services research and public health projects
| Comparative effectiveness of ACE inhibitors for African Americans
(Archived Project) |
|
|---|---|
| Investigator (PI): | Ogedegbe, Gbenga Godwin |
| Performing Organization (PO): |
(Current): New York University, NYU Grossman School of Medicine, Department of Medicine, Division of General Internal Medicine, Center for Healthful Behavior Change / (212) 263-5184 |
| Supporting Agency (SA): | Agency for Healthcare Research and Quality (AHRQ) |
| Initial Year: | 2009 |
| Final Year: | 2012 |
| Record Source/Award ID: | RePorter/R01HS018589 |
| Award Type: | Grant |
| Abstract: | ACE inhibitors are a standard treatment for hypertensive patients. Despite the proven efficacy of these drugs on blood pressure control, there are troubling preliminary data on the safety and effectiveness of these medications in real-world settings, especially among African American patients. Such signals--to date--have not reached the level of evidence required to make it into national guidelines. This application offers a unique opportunity to address this gap in the literature. In a cohort study of patients using data from a clinical data warehouse of 1.8 million patients from New York City's municipal system, we propose to examine potential racial differences in the clinical effectiveness, safety, and adverse effects of ACE inhibitors. Our hypothesis is that 1) ACE inhibitors result in adverse clinical outcomes more often in African Americans compared to Caucasians; 2) ACE inhibitors result in adverse clinical outcomes more often than beta-blockers, thiazide diuretics, or calcium channel blockers among nondiabetic African Americans; and 3) the incremental cost-effectiveness of ACE inhibitors will be less than that for other antihypertensives among nondiabetic African Americans. |
| MeSH Terms: |
|
| Country: | United States |
| State: | New York |
| Zip Code: | 10016 |
| UI: | 20114301 |
| Project Status: | Archived |
